Cerner’s president leaves for Trizetto

  • 15 July 2010

The president of Cerner Corporation is to leave the company and take up a new position as the chief executive of Trizetto Solutions.

Trace Devanney had been due to relocate to London this summer to head up Cerner’s international operations and expansion.

Devanny’s responsibilities will be taken on by the current top management. Long term Cerner chairman and chief executive Neal Patterson will now also take on the title of president.

Trace is a highly experienced and growth-focused leader,” said TriZetto founder and chairman Jeff Margolis. Trizetto focuses on integrated care management with a strong position in the US, plus international clients.

“Having been part of a leadership team that enjoyed tremendous growth at Cerner, I look forward to helping TriZetto capitalize on the many new growth opportunities it has created,” Devanny said ina statement.

Devanny joined Cerner in 1994 and has been the president of Cerner since 1999, a period during which Kansas City based health It company has enjoyed remarkable growth.

During his tenure the company Devanny led the company’s five-fold expansion in revenue, including creating the company’s global presence and brand.

Subscribe to our newsletter

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Sign up

Related News

AI can help build sustainable services – but only if we mitigate its risks

AI can help build sustainable services – but only if we mitigate its risks

Concerns about AI should not stop progress. They should prompt us to think about how to apply such powerful processing, argue Rebecca Hughes and Paul…
Digital Health Coffee Time Briefing ☕

Digital Health Coffee Time Briefing ☕

Your morning summary of digital health news, information and events to know about if you want to be “in the know”. 👇  News 🧠 Cambridge…
NHS Greater Glasgow and Clyde trials tech for infant respiratory disorders

NHS Greater Glasgow and Clyde trials tech for infant respiratory disorders

A wireless device and software developed by NHS Greater Glasgow and Clyde’s West of Scotland Innovation Hub, is being trialled in young patients.